Adolore BioTherapeutics to Present CA8* Neuromodulating Gene Therapy at the 2025 NANS Annual Meeting
DELRAY BEACH, FL / ACCESS Newswire / February 4, 2025 / Adolore BioTherapeutics ("Adolore" or the "Company"), is developing intracellularly-delivered neuromodulators that naturally reduce neuronal excitability to restore balance to the PNS/CNS to treat the underlying root cause of serious neurological disorders, including chronic pain, today announced that Roy C. Levitt, MD, the Company's founder, Chief Medical Officer, and Executive Chairman, Clinical Professor, University of Miami, and Principal Investigator of a NIH, NINDS, HEAL UH3 Award will present at the 2025 North American Neuromodulation Society, ("NANS"), annual meeting being held January 30 - February 1, 2025 in Orlando, Fl.